Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 23, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release fourth quarter and full year 2020 financial results on Tuesday,
View HTML
Toggle Summary Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 11, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the
View HTML
Toggle Summary Intersect ENT to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 1, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West , President & Chief Executive Officer, and Randy Meier , Executive Vice
View HTML
Toggle Summary Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant
Approval Establishes New S Code for PROPEL to Facilitate Specific Coding & Payment MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that
View HTML
Toggle Summary Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020
- Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million - MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 12, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today
View HTML
Toggle Summary CORRECTING and REPLACING - Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2020-- Presentation time in the release dated December 17, 2020 , should read 2 p.m. ET (instead of 5 p.m. ET ). The updated release reads: INTERSECT ENT TO PRESENT AT THE 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Intersect ENT, Inc.
View HTML
Toggle Summary Intersect ENT Announces New Appointments to Executive Leadership Team
Patrick Broderick to Serve as Executive Vice President, General Counsel and Corporate Secretary, and Reyna Fernandez Named as Chief Human Resource Officer MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 17, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear,
View HTML
Toggle Summary Intersect ENT to Participate at Upcoming Investor Conferences
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 5, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that management will participate in the following upcoming investor conferences: Berenberg US CEO
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the third quarter ended September 30, 2020 .
View HTML
Toggle Summary Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020
Preliminary Third Quarter 2020 Revenue Expected to be $22.4 to $22.8 Million MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 15, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary third quarter
View HTML